An AI-designed vaccine against all variants of the coronavirus SARS-CoV-2 – designed using an AI-powered platform developed ...

Parabilis Medicines has revealed the financial details behind its recently announced IPO, hoping to raise up to $475 million ...

And yet, ask most HCPs whether their experience of engaging with pharma has meaningfully improved, and the answer is usually ...

Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...

New trial data with Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran have ...

The London company, based at the King's Cross life sciences and tech hub and led by former scientists at AstraZeneca, ...

Walk through an automotive assembly plant, and you'll see a masterclass in precision. Automated lines, zero-waste workflows, ...

Gedatolisib is a PAM pathway inhibitor – combining PI3K and mTOR inhibition in one molecule – and in the VIKTORIA-1 trial was ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

The Coalition for Epidemic Preparedness Innovations (CEPI) has made $60 million available for clinical trials of vaccines for ...

AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will ...

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows ...